Jul 6, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Ligand Acquired Milestone And Royalty Interest In AstraZeneca IL-9 Program For Asthma
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2170026" data-attributes="member: 124445"><p>Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma. Ligand paid $2.75 million to the Genaera Liquidating Trust in connection with the purchase. This opportunity arose from initial diligence and work conducted by Biotechnology Value Fund, L.P. (BVF)... <a href="http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/sy9jn0hUncw" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/sy9jn0hUncw/3D22" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2170026, member: 124445"] Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma. Ligand paid $2.75 million to the Genaera Liquidating Trust in connection with the purchase. This opportunity arose from initial diligence and work conducted by Biotechnology Value Fund, L.P. (BVF)... [URL="http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/0/da"][IMG]http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/1/da"][IMG]http://feedads.g.doubleclick.net/~a/9oJ70VhRmf2y802QSuf74kCm80I/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/sy9jn0hUncw[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/sy9jn0hUncw/3D22]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top